POS1513-HPR ASSESSMENT OF WORK CAPACITY AND PRODUCTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: M. Fominykh
Journal: Annals of the Rheumatic Diseases (2022)

Background Тhe main task of rheumatologists in the treatment of SLE was to reduce mortality and increase patient survival. At the same time, insufficient attention was paid to improving the quality of life, which includes getting an education, building a career and starting a family. Objectives Study the effect of SLE on the ability to work and productivity of patients. Methods 110 patients with SLE participated in a one-time anonymous survey conducted using Google Forms. A mean age of the patients included in the study was 32.8 ± 7.97 years. A mean duration of SLE was 4 years. 95.45% of patients received glucocorticoids as monotherapy or in combination with immunosuppressive medications: 63.64% hydroxychloroquine, 2.73% methotrexate, 10% azathioprine, 10% cyclosporine, 1.82% mycophenolate mofetil, and 6.36% biological therapy. Work capacity and labor productivity were assessed using the Work Productivity and Activity Improvement (WPAI) questionnaire. Results 110 respondents of working age took part, including 105 women (95.45%) and 5 men (4.55%). A mean age of the study participants was 32.8 ± 7.97 years, women were a mean age 32.6 ± 7.80, and men - 36.4 ± 11.44. The men surveyed have experience of SLE a mean experience of 6.8 ± 4.08 and women 6.4 ± 5.77. High activity disease was observed in 37 people (35.2%), and mild and moderate activity - in 73 (64.8%). 59 women (56%) and 2 men (40%) responded positively to the question about the availability of paid work. Еhe activity of the majority of working patients was associated with mental labor - 58 people (95%). Among the unemployed group of respondents, which made up 44.5% of the total number of survey participants, 76% of respondents associate the lack of paid work with the presence of SLE. Absenteeism was zero in 38 patients (62.3%), which indicates that more than half of the patients did not miss work during all the analyzed days. 6 out of 38 (15.8%) had a high activity disease. 5 people (8.2%) with paid work were absent from the workplace for the entire week under study (absenteeism 100%), of which 4 people had a high activity disease. A mean value of presenteeism in the group of actual workers during the study period was 50.45 ± 28.60% of working time. A mean value of absenteeism was 41.78 ± 36.73%. Work productivty loss in 61 patients with a job was 52.73 ± 30.55%. activity impairment, which was determined in all patients included in the study, was reduced by 51.68 ± 28.44%. In the course of our study, it was revealed that 44.5% of the surveyed patients with SLE of working age do not have a paid job. The absolute majority associate this fact with the influence of the disease on their ability to work. It is also important to say that 23 (37.7%) people out of 61 employees missed work due to their illness. Damage to the musculoskeletal system during the progression of SLE affects the ability to work, labor productivity and daily activity of the adult population is confirmed by the above indicators (presenteeism 50.45 ± 28.60%, absenteeism 41.78 ± 36.73%, work productivty loss 52.73 ± 30.55%, activity impairment 51.68 ± 28.44%). Conclusion Activity disease, functional insufficiency and damage developing as a result of the progression of SLE and ongoing therapy have a direct relationship with a decrease in labor productivity, disability and disability, which is confirmed by the values of presenteeism, absenteeism, work productivty loss and activity impairment. References [1]McCormick N. Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren’s Syndrome: A General Population–Based Study / N. McCormick, C.A. Marra, M. Sadatsafavi, J.A. Kopec // Arthritis care &amp; research. - 2019. - Vol. 71. - no. 1. - S. 142-154. [2]Sokolova C.R. Poor health-related quality of life (HRQOL) and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus (SLE) patients / C.R. Sokolova, R.V. Gamboa Cardenas, M. Medina // Annals of Rheumatic Diseases. - 2019. - Vol. 78. - No. 2. [3] http://www.reillyassociates.net/wpai_general.html Disclosure of Interests None declared